Pharming Group ( (NL:PHARM) ) just unveiled an announcement.
Pharming Group has announced the dosing of the first patient in a Phase II clinical trial for leniolisib, targeting common variable immunodeficiency (CVID) patients with immune dysregulation. This trial marks a significant expansion in Pharming’s efforts to address primary immunodeficiency disorders, aiming to provide a much-needed treatment option for CVID patients who currently have no approved therapies. The trial’s success could enhance Pharming’s position in the market by addressing a larger patient population with unmet medical needs.
More about Pharming Group
Pharming Group is a biopharmaceutical company focused on developing innovative products for the treatment of rare diseases. The company is known for its work in primary immunodeficiency disorders, particularly with its product leniolisib, which is used to treat activated phosphoinositide 3-kinase delta syndrome (APDS).
YTD Price Performance: -10.51%
Average Trading Volume: 13,751
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $590.6M
See more data about PHARM stock on TipRanks’ Stock Analysis page.